



**One Platform.
Endless Possibilities.**

**Annual Meeting of
Stockholders**

DECEMBER 14, 2021 (PST) / DECEMBER 15, 2021 (AEDT)

NASDAQ: RCEL

ASX: AVH

Call To Order

Mr. Lou Panaccio, Chairman of the Board of Avita Medical, Inc.

Welcome

avita^{medical}

Brief Company Overview

Experiencing Technical Difficulties?



In the U.S. please call toll free:

+1 (888) 724-2416



Outside the U.S. please call:

+1 (781) 575-2748



Introduction of Directors, Officers and Advisers

Representatives Present Today



Board of Directors

Louis (Lou) Panaccio
Chair of the Board of Directors
Chair of Today's Meeting

Dr Michael (Mike) Perry
Executive Director and Chief Executive Officer

Professor Suzanne Crowe
Non-executive Director

Jeremy Curnock-Cook
Non-executive Director

Louis (Lou) Drapeau
Non-executive Director

James Corbett
Non-executive Director

Jan Stern Reed
Non-executive Director

Officers

Michael Holder
Chief Financial Officer

Donna Shiroma
General Counsel

Advisers

Chris Cunningham
U.S. Legal Adviser – Partner, K&L Gates LLP

Simon Davidson
Australian Legal Adviser – Lander & Rogers

Breanna Taylor
Australian Legal Adviser – Lander & Rogers

Ashleigh Schultz
Share Registry – Computershare
US Appointment of Inspector of Election

Mark Bottom
Auditor – Grant Thornton LLP

Mark Licciardo
Australian local agent – Mertons Corporate
Services Pty Ltd



Introduction of Independent Registered Public Accounting Firm

Grant Thornton, LLP

Represented by Mark Bottom



Appointment of Inspector of Election

Chairman to appoint



Report By Secretary Of Mailing

Notice of Meeting



Presentation Of List Of Stockholders As Of Record Date

Available upon request



Report Of Quorum

Attendance at this meeting
for a quorum

Opening of the Polls and Overview of Voting Proposals

- Polls for voting on all matters are open
- Proposals – The Board of Directors recommend a vote FOR all of the nominees listed at Proposal 1, and a vote FOR Proposals 2-15



Election of Directors and Approval of Additional Matters

Proposal 1: Election of Directors

To elect five directors to serve a one-year term or until their respective successors have been duly elected and qualified.

1. Louis Panaccio, Chairman of the Board of Directors
2. Dr. Michael Perry, Director and Chief Executive Officer
3. Jeremy Curnock Cook, Director
4. Louis Drapeau, Director
5. Professor Suzanne Crowe, Director
6. James Corbett
7. Jan Stern Reed

Proposal 2:

To ratify the appointment of Grant Thornton, LLP as the Company's independent public accountants for the fiscal year ending June 30, 2022.

Proposal 3:

To approve an amendment to the Company's Amended and Restated Bylaws to provide for the ability of the Company to implement a sales facility with respect to those CDI holders that hold at the relevant time less than a marketable parcel of the Company's CDIs for the purposes of the ASX Listing Rules and ASX Settlement Operating Rules, on the terms and conditions set out in this Proxy Statement.

Proposal 4:

To ratify the issue of 3,214,250 shares of common stock in the capital of the Company with an issue price of US\$21.50 per share that were issued pursuant to an underwritten registered public offering that was completed in March 2021 on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 7.4 and for all other purposes.

Proposal 5:

To approve, for the purposes of ASX Listing Rule 10.17 and the Company's Amended and Restated Bylaws and for all other purposes, that the maximum aggregate annual cash fee pool from which the non-executive directors of the Company may be paid for their services as members of the board of directors of the Company be increased from US\$600,000 per annum to US\$750,000 per annum.

Proposal 6:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Louis Panaccio, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 7:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Professor Suzanne Crowe, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 8:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Jeremy Curnock Cook, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 9:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Louis Drapeau, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 10:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 11:

To approve the grant of restricted stock units to acquire 8,675 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 4,925 shares of common stock of the Company (which may be represented by CDIs) to Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Mr. James Corbett being appointed as a new non-executive director of the Company during 2021.

Proposal 12:

To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Ms. Jan Stern Reed, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 13:

To approve the grant of restricted stock units to acquire 8,675 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 4,925 shares of common stock of the Company (which may be represented by CDIs) to Ms. Jan Stern Reed, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Ms. Jan Stern Reed being appointed as a new non-executive director of the Company during 2021.

Proposal 14:

To approve the grant of restricted stock units to acquire 95,280 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 55,200 shares of common stock of the Company (which may be represented by CDIs) to the Company's Chief Executive Officer, Dr. Michael Perry, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 15:

Say On Pay: Advisory vote to approve the compensation of the Company's named executive officers.

Proposal 16:

- **To transact such other business as may properly come before the meeting or any adjournment or adjournments.**
 - **No other business has come before the meeting to be considered at this time.**



Closing of Polls

The polls are about to close so if you have not yet voted,
please do so.

We will announce the results of the voting as soon as possible following the close of this meeting via announcements to be filed with the U.S. Securities and Exchange Commission and the Australian Securities Exchange.



Adjournment of Meeting and General Question and Answer Period

The formal business of the meeting is now closed.

We invite you to now ask any questions you may have as it relates to the content of today's meeting. Please follow the instructions provided on the Virtual Meeting Screen. Any questions regarding the Company's financials and business operation matters should be addressed on our earnings call scheduled tomorrow afternoon, Wednesday, December 15, 2021 at 1:30pm (PT) (being 8:30am AEDT Thursday, December 16, 2021).



Conclusion of Meeting

avita^{medical}



avita
medical

Thank you!